Pfizer ready for post-COVID gains

Pfizer’s COVID-19 vaccine has generated big gains for investors. While demand is now fading as the pandemic eases, new booster shots that target the Omicron variant should continue to spur its profits.
The company is using its higher earnings to buy smaller drugmakers. Pfizer’s expertise should… Read More

We prefer the parents, not the spinoffs

These two overseas firms are spinning off some of their smaller businesses, which helps unlock value. For your new buying, we still like their shares, but we suggest holding off for now on buying additional shares in their spinoffs.
ABB LTD. ADRs $27 is a buy. This… Read More

These spinoffs are still worth holding

Both these spinoffs are off to a slow start as they restructure their operations. We feel their moves will ultimately pay off, but it’s better to hold off new buying right now.
VIATRIS INC. $11 is a hold. The company (New York symbol VTRS; Manufacturing & Industry sector;… Read More

New firms show the power of brands

New firms spun off from larger companies sometimes rise quickly, like Carrier and Otis. That’s probably because investors are familiar with their products and like their prospects. However, others such as Viatris and Kyndryl, are more obscure and need a few years to build a.. Read More

Haleon sale funds new acquisition

PFIZER INC. $49 is a buy. The prescription drugmaker (New York symbol PFE; Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $274.4 billion; Dividend yield: 3.3%; Takeover Target Rating: Medium; www.pfizer.com) merged its consumer drug business with GlaxoSmithKline (New York symbol GSK) in 2019.
Glaxo now plans to… Read More